The U.S. Food and Drug Administration (FDA) is advising that the opioid addiction medications buprenorphine and methadone should not be withheld from patients taking benzodiazepines or other drugs that depress the central nervous system (CNS). The combined use of these drugs increases the risk of serious side effects; however, the harm caused by untreated opioid addiction can outweigh these risks. Careful medication management by health care professionals can reduce these risks. They are requiring this information to be added to the buprenorphine and methadone drug labels along with detailed recommendations for minimizing the use of medication-assisted treatment (MAT) drugs and benzodiazepines together.
June 29, 2017
January 23, 2018
- DHHS Announces Grants to Local Health Departments to Address the Opioid Crisis
- Patient Resources for Safe Medication Storage and Disposal
- New North Carolina Controlled Substance Reporting System (CSRS) Now Available
- Addiction Medicine Leaders Applaud Signing of Historic Opioid Legislation Into Law
- Resistant Alcohol Withdrawal (RAW): A Retrospective Case-Control Study